Abstract:13a-(S)-3-pivaloyloxyl-6,7-dimethoxyphenanthro(9,10-b)-indolizidine (CAT3) is a novel oral anti-glioma pro-drug with a potent anti-tumor effect against temozolomide-resistant glioma. 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro(9,10-b)-indolizidine (PF403) is the active in vivo lipase degradation metabolite of CAT3. Both CAT3 and PF403 can penetrate the blood–brain barrier to cause an anti-glioma effect. However, PF403, which is produced in the gastrointestinal tract and plasma, causes significant gastrointestinal side effects, limiting the clinical application of CAT3. The objective of this paper was to propose a metabolism modification for CAT3 using a self-microemulsifying drug delivery system (SMEDDS), in order to reduce the generation of PF403 in the gastrointestinal tract and plasma, as well as increase the bioavailability of CAT3 in vivo and the amount of anti-tumor substances in the brain. Thus, a CAT3-loaded self-microemulsifying drug delivery system (CAT3-SMEDDS) was prepared, and its physicochemical characterization was systematically carried out. Next, the pharmacokinetic parameters of CAT3 and its metabolite in the rats’ plasma and brain were measured. Furthermore, the in vivo anti-glioma effects and safety of CAT3-SMEDDS were evaluated. Finally, Caco-2 cell uptake, MDCK monolayer cellular transfer, and the intestinal lymphatic transport mechanisms of SMEDDS were investigated in vitro and in vivo. Results show that CAT3-SMEDDS was able to form nanoemulsion droplets in artificial gastrointestinal fluid within 1 min, displaying an ideal particle size (15–30 nm), positive charge (5–9 mV), and controlled release behavior. CAT3-SMEDDS increased the membrane permeability of CAT3 by 3.9-fold and promoted intestinal lymphatic transport. Hence, the bioavailability of CAT3 was increased 79% and the level of its metabolite, PF403, was decreased to 49%. Moreover, the concentrations of CAT3 and PF403 were increased 2–6-fold and 1.3–7.2-fold, respectively, in the brain. Therefore, the anti-glioma effect in the orthotopic models was improved with CAT3-SMEDDS compared with CAT3 in 21 days. Additionally, CAT3-SMEDDS reduced the gastrointestinal side effects of CAT3, such as severe diarrhea, necrosis, and edema, and observed less inflammatory cell infiltration in the gastrointestinal tract, compared with the bare CAT3. Our work reveals that, through the metabolism modification effect, SMEDDS can improve the bioavailability of CAT3 and reduce the generation of PF403 in the gastrointestinal tract and plasma. Therefore, it has the potential to increase the anti-glioma effect and reduce the gastrointestinal side effects of CAT3 simultaneously.

In Vivo Anti-Tumor Activity of Polypeptide HM-3 Modified by Different Polyethylene Glycols (PEG)

Site-specific Modification of Anti-Angiogenesis Peptide HM-3 by Polyethylene Glycol Molecular Weight of 20 Kda.

In Vivo Pharmacokinetics, Immunogenicity and Mechanism of PEGylated Antitumor Polypeptide

Studies of poly(ethylene glycol) modification of HM-3 polypeptides.

An Integrin Αvβ3 Antagonistic Modified Peptide Inhibits Tumor Growth Through Inhibition of the ERK and AKT Signaling Pathways.

[Corrigendum] in Vitro and in Vivo Activities of an Antitumor Peptide HM-3: A Special Dose-Efficacy Relationship on an HCT‑116 Xenograft Model in Nude Mice.

Antitumor effects of peptide HM-3 against non-small cell lung cancer xenografts in nude mice

PEGylated HM-3 presents anti-rheumatic bioactivity by inhibiting angiogenesis and inflammation

Albumin Fusion at the N-Terminus or C-Terminus of HM-3 Leads to Improved Pharmacokinetics and Bioactivities

Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities

Preparation of a novel neovessel-targeted PEGylated liposome formulation

Anti-Tumor Study of H6, a 4-Substituted Coumarins Derivative, Loaded Biodegradable Self-Assembly Nano-Micelles in Vitro and in Vivo.

&Lt;em>n</em>-(3-hydroxymethyl-&beta;-carboline-1-yl-ethyl-2-yl)-l-phe: Development Toward a Nanoscaled Antitumor Drug Capable of Treating Complicated Thrombosis and Inflammation

Superior anti-neoplastic activities of triacontanol-PEG conjugate: synthesis, characterization and biological evaluations.

Drug-Polymer Interaction, Pharmacokinetics and Antitumor Effect of PEG-PLA/Taxane Derivative TM-2 Micelles for Intravenous Drug Delivery

Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin.

Improved Safety and Anti-Glioblastoma Efficacy of CAT3-Encapsulated SMEDDS through Metabolism Modification

Anti-tumor Efficiency of NGR-modified PEG-PLGA Micelles Containing Paclitaxel: in Vitro and in Vivo

Combined Administration of PTX and S-HM-3 in TPGS/Solutol Micelle System for Oncotarget Therapy

Effect of the Pegylation of Trimeric Β Peptide on It's Anti-metastasis Activity

Preparation, Characterization and in Vivo Antitumor Evaluation of a Micellar Formulation of Camptothecin Prodrug